WZ3146 Size:10mg solid In contrast to type II

In contrast to type II inhibitors of CDK8 and CDK19

40 μM) inhibits pancreatic cancer cell invasion and cell growth

Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma

a dramatic increase in caspase-3 activity (6-10-fold relative to control or TRAIL alone) is observed

also known CMP 6 or JAK Inhibitor I

WZ3146 Size:10mg solid In contrast to type IIWZ 3146 is a covalent or irreversible pyrimidine based EGFR inhibitor against EGFR T790M. WZ 3146 was identified by screening an irreversible kinase inhibitor library specifically against EGFR T790M. WZ 3146 potently suppresses the growth of EGFR T790M containing cell lines and inhibits EGFR phosphorylation. WZ 3146 is also effective in murine models of lung cancer driven by EGFR T790M. WZ 3146 may be clinically more effective and better tolerated